Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.140
+0.030 (1.42%)
Aug 4, 2026, 1:28 PM EDT - Market open

Lipocine Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1.571.9811.23.070.5-
Revenue Growth
409.37%-82.35%264.67%514.16%--
Gross Profit
1.571.9811.23.070.5-
Selling, General & Admin
3.953.7654.94.065.33
Research & Development
10.198.587.3510.188.567.67
Total Operating Expenses
14.1412.3512.3515.0812.6213
Operating Income
-12.57-10.37-1.16-17.93-12.123.15
Interest Income
0.720.741.151.370.55-0.14
Other Non-Operating Income (Expense)
--0.020.210.82-3.64
Total Non-Operating Income (Expense)
0.720.741.161.581.36-3.78
Pretax Income
-11.85-9.630.01-16.35-10.76-0.63
Provision for Income Taxes
000000
Net Income
-11.85-9.630.01-16.35-10.76-0.63
Net Income Attributable to Preferred Dividends
---0--
Net Income to Common
-9.48-9.630.01-16.35-10.76-0.63
Net Income Growth
------
Shares Outstanding (Basic)
755555
Shares Outstanding (Diluted)
765555
Shares Change
24.91%5.27%2.90%0.26%1.98%57.35%
EPS (Basic)
-1.87-1.77--3.10-2.06-0.17
EPS (Diluted)
-1.87-1.77--3.14-2.15-0.17
EPS Growth
------
Free Cash Flow
-11.19-9.76-1.31-11.88-12.1-4.42
Free Cash Flow Growth
------
Free Cash Flow Per Share
-1.65-1.71-0.24-2.25-2.30-0.86
Gross Margin
100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-800.82%-524.69%-10.31%-583.92%-2423.87%-
Profit Margin
-755.13%-487.05%0.07%-532.50%-2151.73%-
FCF Margin
-713.03%-493.79%-11.71%-386.84%-2420.53%-
EBITDA
-12.51-10.31-1.11-17.9-12.113.15
EBITDA Margin
-797.09%-521.61%-9.95%-582.99%-2421.98%-
EBIT
-12.57-10.37-1.16-17.93-12.123.15
EBIT Margin
-800.82%-524.69%-10.31%-583.92%-2423.87%-
Effective Tax Rate
-0.00%-0.00%7.54%-0.00%-0.01%-0.03%
SEC Filings: 10-K · 10-Q